RE
Revelation Biosciences, Inc.
REVB · NASDAQ
$0.87 -2.24% (-$0.02)
1M -15.51%
Market Cap $3.40M
P/E Ratio -
Div. Yield -
ROE 100.20%
Bulios Fair Price
$0.45
48.3% downside
Current Price
$0.87
Undervalued Fair Value Overvalued
According to Bulios Fair Price, REVB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.34x
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 103.44%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 104.28%
Asset turnover 0.00x
ROE 100.20%
Debt
100 /100
Low Debt/Equity 0.07x
Current ratio 6.21x
Int. coverage N/A
Stability
19 /100
Unstable Beta -0.17x
Profitable years 0
EPS volatility 594.17%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about REVB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
James Rolke
Employees
8
Headquarters
San Diego
Upcoming events
05 NOV
Earnings
Upcoming earnings report